The TAIL-PrEP study aims to find the best ways to help people safely stop using long-acting injectable medications for HIV prevention, specifically cabotegravir (cab-LA) and lenacapavir (LEN). These medications are very effective, but stopping them can be tricky because the drug stays in the body for a while, which could lead to drug resistance if HIV is acquired. This study will test an intervention that includes monthly drug level monitoring and personalized coaching for those stopping cab-LA, or a one-time coaching session for those considering stopping cab-LA or LEN. The goal is to see if this approach is acceptable and practical for patients. You might be able to join if you are at least 18 years old, HIV-negative, speak English, and have internet access for online calls. The study is currently recruiting about 30 participants.

Study design

This is an interventional study with an unclear phase, planning to enroll 30 participants. It will assess the acceptability and feasibility of the TAIL-PrEP intervention.

What's involved

For those discontinuing cab-LA, commitments include monthly cab-LA monitoring with self-collected specimens and monthly HIV prevention coaching. For those considering discontinuing cab-LA or LEN, it involves a one-time HIV prevention coaching session.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints, acceptability and feasibility, are measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.